Olopatadine nasal Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Oct 7, 2021.
Olopatadine nasal is also known as: Patanase
Olopatadine nasal Pregnancy Warnings
Animal reproductive studies have revealed evidence of treatment-related effects on fetuses/pups. Following high oral doses in rat and rabbits, there was evidence of a decrease in the number of live fetuses, reduced viability, and decreased body weights. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
US FDA pregnancy category: C
Olopatadine nasal Breastfeeding Warnings
This drug has been found in the milk of nursing rats following oral administration.
This drug should be used by nursing mothers only if the potential benefit to the mother outweighs the potential risk to the infant
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc (2008):
References for breastfeeding information
- "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc (2008):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
